e-learning
resources
Stockholm 2007
Sunday 16.09.2007
Novel therapeutic targets and disease markers in pulmonary pathology
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Transcriptional regulation of the human cystic fibrosis transmembrane conductance regulator gene promoter by peroxisome proliferator-activated receptor γ
A. Macdonald, D. Nahirney, M. Duszyk (Edmonton, AB, Canada)
Source:
Annual Congress 2007 - Novel therapeutic targets and disease markers in pulmonary pathology
Session:
Novel therapeutic targets and disease markers in pulmonary pathology
Session type:
Oral Presentation
Number:
405
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Macdonald, D. Nahirney, M. Duszyk (Edmonton, AB, Canada). Transcriptional regulation of the human cystic fibrosis transmembrane conductance regulator gene promoter by peroxisome proliferator-activated receptor γ. Eur Respir J 2007; 30: Suppl. 51, 405
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Peroxisome proliferator activated receptor gamma (PPARγ) agonist rosiglitizone inhibits upregulation of mucin gene expression in two airway epithelial cell lines
Source: Eur Respir J 2005; 26: Suppl. 49, 97s
Year: 2005
Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD
Source: Eur Respir J 2007; 30: 245-252
Year: 2007
Activation of airway epithelial cell inhibited by peroxisome proliferator-activated receptor γ
Source: Eur Respir J 2006; 28: Suppl. 50, 229s
Year: 2006
Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease
Source: Eur Respir J 2006; 28: Suppl. 50, 856s
Year: 2006
Diminished peroxisome proliferator-activated receptor (PPAR) regulation as a potential mechanism for the persistent inflammation in chronic obstructive pulmonary disease
Source: Eur Respir Rev 2006; 15: 211-212
Year: 2006
The effect of peroxisome proliferator-activated receptor-? ligands on in vitro and in vivo models of COPD
Source: Eur Respir J 2014; 43: 409-420
Year: 2013
The interaction of glucocorticoid and peroxisome proliferator-activated receptor γ agonist in asthmatic mice
Source: Eur Respir J 2006; 28: Suppl. 50, 226s
Year: 2006
Involvement of C/EBPbeta and delta in lung glucocorticoid signaling
Source: Eur Respir J 2002; 20: Suppl. 38, 372s
Year: 2002
The effects of exercise training on peroxisome proliferator-activated receptor (PPAR) expression in skeletal muscle in COPD
Source: Annual Congress 2009 - Emerging physiology behind pulmonary rehabilitation
Year: 2009
Relationship between peroxisome proliferator-activated receptor α and neutrophils in COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 452s
Year: 2004
Regulation of eotaxin gene transcription by peroxisome proliferator-activated receptor γ agonists in human airway smooth muscle cells: interactions with glucocorticoids and β
2
-agonists
Source: Annual Congress 2005 - Inflammation and the airway smooth muscle: cellular and pharmacological interactions
Year: 2005
The role of peroxisome proliferator-activated receptor γ in pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary circulation II
Year: 2009
Role of exogenous ligands for the peroxisome proliferator-activated receptor-β/δ in the development of bleomycin-induced lung injury
Source: Annual Congress 2010 - Cell biology and immunology of lung disease
Year: 2010
Impacts of peroxisome proliferator-activated receptor gamma activation on cigarette smoke-induced exacerbated response to bacteria
Source: Eur Respir J 2015; 45: 191-200
Year: 2015
Peroxisome proliferator-activated receptors: a therapeutic target in COPD?
Source: Eur Respir J 2008; 31: 502-508
Year: 2008
Role of peroxisome proliferator activated receptor γ in COPD
Source: Annual Congress 2009 - Airway inflammation and host defence
Year: 2009
The pattern recognition receptor Nod1 activates CCAAT/enhancer binding protein β signalling in lung epithelial cells
Source: Eur Respir J 2007; 30: 214-222
Year: 2007
Muscarinic receptor stimulation differentially regulates extracellular matrix gene expression in lung fibroblasts
Source: Annual Congress 2011 - The ageing pulmonary interstitium
Year: 2011
The inhibitory effect of peroxisome proliferator-activated receptor-γ ligands on malignant pleural mesothelioma cell growth
Source: Annual Congress 2008 - Biology and diagnosis of thoracic tumours
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept